Johnson Investment Counsel Inc. Has $2.21 Million Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Johnson Investment Counsel Inc. increased its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 23.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 20,730 shares of the specialty pharmaceutical company’s stock after acquiring an additional 3,890 shares during the period. Johnson Investment Counsel Inc.’s holdings in Jazz Pharmaceuticals were worth $2,213,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Rise Advisors LLC boosted its holdings in Jazz Pharmaceuticals by 2,255.6% during the first quarter. Rise Advisors LLC now owns 212 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 203 shares in the last quarter. Versant Capital Management Inc lifted its position in shares of Jazz Pharmaceuticals by 13,450.0% during the 2nd quarter. Versant Capital Management Inc now owns 271 shares of the specialty pharmaceutical company’s stock worth $29,000 after buying an additional 269 shares during the period. GAMMA Investing LLC boosted its stake in Jazz Pharmaceuticals by 65.5% in the 2nd quarter. GAMMA Investing LLC now owns 293 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 116 shares in the last quarter. Cape Investment Advisory Inc. grew its position in Jazz Pharmaceuticals by 14,600.0% in the fourth quarter. Cape Investment Advisory Inc. now owns 294 shares of the specialty pharmaceutical company’s stock valued at $36,000 after acquiring an additional 292 shares during the period. Finally, Gladius Capital Management LP acquired a new position in Jazz Pharmaceuticals during the second quarter worth $33,000. Institutional investors own 89.14% of the company’s stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.20% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently commented on JAZZ. StockNews.com upgraded shares of Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, August 1st. UBS Group decreased their price objective on shares of Jazz Pharmaceuticals from $117.00 to $113.00 and set a “neutral” rating on the stock in a research note on Tuesday, July 2nd. Wells Fargo & Company reduced their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating on the stock in a report on Thursday, August 1st. HC Wainwright reaffirmed a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, August 1st. Finally, Piper Sandler reduced their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating on the stock in a research note on Thursday, August 1st. Four equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Trading Up 2.2 %

Shares of NASDAQ JAZZ opened at $108.79 on Friday. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $137.38. The firm has a market capitalization of $6.72 billion, a P/E ratio of 22.43, a P/E/G ratio of 1.31 and a beta of 0.57. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 2.02. The company’s 50 day simple moving average is $109.88 and its 200 day simple moving average is $111.71.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.